Close Menu

target amplification

The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics. 

The company has added three recently issued patents to the suit, filed Jan. 27, all covering methods for amplifying and sequencing nucleic acids.

The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.

A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.

The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.

The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.

The European Commission recently awarded Cergentis a €1.2 million grant to support the development of its TLA technology for use in FFPE samples.

Heat-Seq, scheduled to launch in the second quarter, uses empirically tested molecular inversion probes.

Pages

Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.

Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.

Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.

In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.